Antigenics starts Oncophage melanoma Phase III

AGEN started a U.S. and European Phase III study of its Onchophage cancer vaccine ( HSPPC-96) to treat metastatic melanoma. The 200-patient trial will compare Oncophage to standard care. Oncophage als...